Format

Send to

Choose Destination
Stroke. 2020 Feb;51(2):542-548. doi: 10.1161/STROKEAHA.119.027225. Epub 2019 Dec 17.

Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.

Author information

1
From the Department of Neurology (C.A.-L., M.S.W., J.L.-E), Seattle Children's Hospital, WA.
2
Department of Radiology (D.W.W.S.), Seattle Children's Hospital, WA.
3
Enterprise Analytics (A.C., D.B.), Seattle Children's Hospital, WA.
4
Department of Neurology, Alberta Children's Hospital, Calgary, Canada (A.K.).
5
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD (R.J.F.).
6
Department of Neurology, University of Kansas, Kansas City (M.G.A.).
7
Department of Neurology, The Royal Children's Hospital, Melbourne, VIC, Australia (M.T.M.).
8
Department of Neurology, Children's Medical Center at Dallas, TX (M.M.D.).
9
Department of Hematology, Cook Children's Medical Center, Fort Worth, TX (M.T.).
10
Department of Neurology, Boston Children's Hospital, MA (M.J.R.).
11
Department of Pediatric Hematology-Oncology, Massachusetts General Hospital, Boston (E.F.G.).
12
Department of Neurology, Stanford University, Palo Alto, CA (S.L.).
13
Department of Neurology, Ann & Robert H Lurie Children's Hospital of Chicago, IL (J.E.K.).
14
Department of Neurology, Children's Hospital of Eastern Ontario, Ottawa, Canada (H.J.M.).
15
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia (R.N.I.).

Abstract

Background and Purpose- Data regarding the safety and efficacy of intravenous tPA (tissue-type plasminogen activator) in childhood acute arterial ischemic stroke are inadequate. The TIPS trial (Thrombolysis in Pediatric Stroke; National Institutes of Health grant R01NS065848)-a prospective safety and dose-finding trial of intravenous tPA in acute childhood stroke-was closed for lack of accrual. TIPS sites have subsequently treated children with acute stroke in accordance with established institutional protocols supporting data collection on outcomes. Methods- Data on children treated with intravenous tPA for neuroimaging-confirmed arterial ischemic stroke were collected retrospectively from 16 former TIPS sites to establish preliminary safety data. Participating sites were required to report all children who were treated with intravenous tPA to minimize reporting bias. Symptomatic intracranial hemorrhage (SICH) was defined as ECASS (European Cooperative Acute Stroke Study) II parenchymal hematoma type 2 or any intracranial hemorrhage associated with neurological deterioration within 36 following tPA administration. A Bayesian beta-binomial model for risk of SICH following intravenous tPA was fit using a prior distribution based on the risk level in young adults (1.7%); to test for robustness, the model was also fit with uninformative and conservative priors. Results- Twenty-six children (age range, 1.1-17 years; median, 14 years; 12 boys) with stroke and a median pediatric National Institutes of Health Stroke Scale score of 14 were treated with intravenous tPA within 2 to 4.5 hours (median, 3.0 hours) after stroke onset. No patient had SICH. Two children developed epistaxis. Conclusions- The estimated risk of SICH after tPA in children is 2.1% (95% highest posterior density interval, 0.0%-6.7%; mode, 0.9%). Regardless of prior assumption, there is at least a 98% chance that the risk is <15% and at least a 93% chance that the risk is <10%. These results suggest that the overall risk of SICH after intravenous tPA in children with acute arterial ischemic stroke, when given within 4.5 hours after symptom onset, is low.

KEYWORDS:

adult; child; humans; stroke; tissue-type plasminogen activator

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center